PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of aacPermissionsJournals.ASM.orgJournalAAC ArticleJournal InfoAuthorsReviewers
 
Antimicrob Agents Chemother. 2010 April; 54(4): 1613–1615.
Published online 2010 January 25. doi:  10.1128/AAC.01637-09
PMCID: PMC2849356

Activity of the Investigational Fluoroquinolone Finafloxacin against Ciprofloxacin-Sensitive and -Resistant Acinetobacter baumannii Isolates [down-pointing small open triangle]

Abstract

This study compared the activity of finafloxacin, a novel fluoroquinolone which shows enhanced activity under acidic pH, and that of ciprofloxacin against Acinetobacter baumannii under standard conditions (pH 7.2) and at a pH of 5.8. Overall, finafloxacin demonstrated superior activity to ciprofloxacin under acidic conditions. Furthermore, finafloxacin showed comparable activity to ciprofloxacin at pH 7.2. Hence, finafloxacin could be a promising new antimicrobial agent for the treatment of A. baumannii infections at acidic body compartments.

The continuing spread of multidrug-resistant Acinetobacter baumannii is of serious concern to health professionals and often leaves few therapeutic options (7). Fluoroquinolones have in the past shown good activity against A. baumannii (8); however, over the past decade there has been a constant rise in fluoroquinolone resistance (11). Resistance to fluoroquinolones in A. baumannii is mediated primarily by stepwise selection of mutations in the drug targets gyrA and parC. The first step is a gyrA mutation, most commonly leading to a Ser83-Leu substitution (18). This is often sufficient to render the isolate intermediate or fully resistant to ciprofloxacin. A second mutation, in parC, most often causing a Ser80-Leu substitution, usually leads to high-level resistance to all fluoroquinolones (17, 19). In addition, drug efflux contributes to fluoroquinolone resistance (9, 13).

Finafloxacin (Fig. (Fig.1)1) is a novel fluoroquinolone currently undergoing phase II clinical trials. This drug shows enhanced activity under acidic pH, where other fluoroquinolones display decreased activity. Infected body sites can have a significantly lower pH than healthy tissue (Table (Table1).1). The objective of this study was to determine the activity of finafloxacin and ciprofloxacin against A. baumannii isolates with characterized gyrA and parC genes under standard testing conditions and under an acidic pH.

FIG. 1.
Structure of finafloxacin HCl.
TABLE 1.
pH values as measured for different body fluids and tissues in the presence or absence of infectiona

A total of 68 previously characterized genotypically unrelated ciprofloxacin-sensitive and -resistant A. baumannii clinical isolates were investigated (Table (Table2)2) (9, 13, 19). Of these, 18 are wild-type GyrA/ParC, 26 have a GyrA substitution, and 24 have a double GyrA/ParC substitution. Two isolates overexpress the efflux pump adeB compared to their isogenic parent strains (9, 13). Ciprofloxacin and finafloxacin MICs were determined by agar dilution under standard conditions (pH 7.2) (5), and at a pH of 5.8. pH 5.8 was chosen as it is representative of a number of infected body sites (lower respiratory tract, skin, stomach mucosa) and is the mean pH of urine during urinary tract infection. Ciprofloxacin and finafloxacin powders were supplied by their respective manufacturers (Bayer AG, Wuppertal, Germany, and MerLion Pharmaceuticals GmbH, Berlin). Mueller-Hinton agar (Oxoid, Wesel, Germany) was prepared following the manufacturer's instructions, and the pH was adjusted by the addition of HCl prior to pouring antibiotic-containing plates. The pH of the agar was checked once solidified. Ciprofloxacin- and finafloxacin-containing plates were prepared on the same day using freshly prepared media, and MICs were determined simultaneously.

TABLE 2.
Agar dilution MICs of ciprofloxacin (CIP) and finafloxacin (FIN) under normal pH (7.2) and acidic (pH 5.8) conditions against characterized A. baumannii isolates

Results are summarized in Table Table2.2. At normal pH (pH 7.2), finafloxacin had comparable activity to ciprofloxacin against wild-type GyrA/ParC isolates, with both having MIC50 and MIC90 values of 0.25 μg/ml and 1 μg/ml, respectively. At the lower pH, finafloxacin recorded MIC50 and MIC90 values of 0.12 μg/ml, compared to 2 μg/ml and 4 μg/ml for ciprofloxacin, respectively.

Comparable finafloxacin and ciprofloxacin activities at normal pH were also found in isolates with a GyrA substitution, with the majority of isolates recording either the same MIC or a finafloxacin MIC within one dilution of the respective ciprofloxacin MIC. However, at the lower pH, finafloxacin MIC50 and MIC90 values were both lowered from 16 μg/ml to 2 μg/ml, compared to ciprofloxacin MIC50 and MIC90 rising from 8 μg/ml and 16 μg/ml, respectively, to 32 μg/ml and >128 μg/ml, respectively.

Finafloxacin was more potent than ciprofloxacin against isolates with the double GyrA/ParC substitution tested under normal conditions, Finafloxacin recorded MIC50 and MIC90 values of 32 μg/ml and 64 μg/ml, respectively, compared to ciprofloxacin MIC50 and MIC90 values of 128 μg/ml and >128 μg/ml, respectively. Activity of finafloxacin at pH 5.8 showed an up to 16-fold lowering of MIC, with MIC50 and MIC90 values of 4 μg/ml and 8 μg/ml, respectively. In contrast, all these isolates recorded a ciprofloxacin MIC of >128 μg/ml. Two isolates which have been shown to overexpress the efflux pump AdeB also exhibited up to a 16-fold reduction in finafloxacin MIC under acidic conditions.

The effect of pH on antimicrobial activity is well known and is dependent upon the antimicrobial agent (16). Acidification of media incubated in 5% CO2 affects macrolide activity (10), and ciprofloxacin activity is reduced in acidic sites such as the phagolysosome (1). In the present study we found a polar effect of the fluoroquinolones ciprofloxacin and finafloxacin under acidic compared to standard conditions.

Finafloxacin has been shown to exhibit lowered MICs against a range of pathogenic bacteria under acidic conditions compared to at neutral pH, whereas ciprofloxacin and levofloxacin MICs were higher under acidic conditions (20). The mechanism of enhanced or reduced finafloxacin activity is thought to result, at least in part, from the different physiochemical properties of the fluoroquinolone molecules. Many fluoroquinolones are zwitterionic in character, and thus their lipophilicity and partitioning across biological membranes are influenced by the presence of different ionizable groups and the pH of the surroundings (6, 12, 14).

Another mechanism may be the result of changes in bacterial gene expression leading to greater drug diffusion/accumulation (more activity) or less diffusion/accumulation (reduced activity). For example, in Serratia marcescens the porins OmpF and OmpC are induced by alkaline and acidic conditions, respectively, while norfloxacin accumulation is reduced under acidic conditions compared to accumulation under neutral or alkaline conditions (2, 3). A. baumannii shows an innate resistance to many antimicrobials which is attributed to its low outer membrane permeability (15), and fluoroquinolones are known substrates of their efflux pumps (13). It is not known what effect the pH has on porin or efflux pump expression in A. baumannii; however, in this study, overexpression of adeB isolates results in lower finafloxacin MICs under acidic pH than under standard conditions. Whether this effect is due to reduced expression of the AdeB efflux pump system, due to other efflux pumps, or porin mediated remains to be determined.

In summary, finafloxacin demonstrated superior activity to ciprofloxacin under acidic conditions against ciprofloxacin-sensitive and -resistant A. baumannii. Furthermore, finafloxacin showed comparable activity to ciprofloxacin at pH 7.2 and could be a promising new antimicrobial agent for the treatment of A. baumannii infections at acidic body compartments.

Acknowledgments

The contribution of P.G.H. and H.S. was supported by the German Federal Ministry of Research and Education (BMBF grant 01KI0771). P.G.H. was the recipient of a travel grant from MerLion Pharmaceuticals GmbH.

Footnotes

[down-pointing small open triangle]Published ahead of print on 25 January 2010.

REFERENCES

1. Akova, M., D. Gur, D. M. Livermore, T. Kocagoz, and H. E. Akalin.1999. In vitro activities of antibiotics alone and in combination against Brucella melitensis at neutral and acidic pHs. Antimicrob. Agents Chemother. 43:1298-1300. [PMC free article] [PubMed]
2. Begic, S., and E. A. Worobec.2006. Regulation of Serratia marcescens ompF and ompC porin genes in response to osmotic stress, salicylate, temperature and pH. Microbiology 152:485-491. [PubMed]
3. Begic, S., and E. A. Worobec.2007. Fluoroquinolone resistance of Serratia marcescens: sucrose, salicylate, temperature, and pH induction of phenotypic resistance. Can. J. Microbiol. 53:1239-1245. [PubMed]
4. Byerly, T. C.1953. Handbook of biological data. Science 118:3. [PubMed]
5. Clinical and Laboratory Standards Institute.2007. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. 7th ed. Approved standard M7-A7. CLSI, Wayne, PA.
6. Dalhoff, A., S. Schubert, and U. Ullmann.2005. Effect of pH on the in vitro activity of and propensity for emergence of resistance to fluoroquinolones, macrolides, and a ketolide. Infection 33:36-43. [PubMed]
7. Dijkshoorn, L., A. Nemec, and H. Seifert.2007. An increasing threat in hospitals: multidrug-resistant Acinetobacter baumannii. Nat. Rev. Microbiol. 5:939-951. [PubMed]
8. Higgins, P. G., K. Coleman, and S. G. B. Amyes.2000. Bactericidal and bacteriostatic activity of gemifloxacin against Acinetobacter spp. in vitro. J. Antimicrob. Chemother. 45:71-77. [PubMed]
9. Higgins, P. G., H. Wisplinghoff, D. Stefanik, and H. Seifert.2004. Selection of topoisomerase mutations and overexpression of adeB mRNA transcripts during an outbreak of Acinetobacter baumannii. J. Antimicrob. Chemother. 54:821-823. [PubMed]
10. Johnson, M. M., S. L. Hill, and L. J. V. Piddock.1999. Effect of carbon dioxide on testing of susceptibilities of respiratory tract pathogens to macrolide and azalide antimicrobial agents. Antimicrob. Agents Chemother. 43:1862-1865. [PMC free article] [PubMed]
11. Karlowsky, J. A., D. C. Draghi, M. E. Jones, C. Thornsberry, I. R. Friedland, and D. F. Sahm.2003. Surveillance for antimicrobial susceptibility among clinical isolates of Pseudomonas aeruginosa and Acinetobacter baumannii from hospitalized patients in the United States, 1998 to 2001. Antimicrob. Agents Chemother. 47:1681-1688. [PMC free article] [PubMed]
12. Nikaido, H., and D. G. Thanassi.1993. Penetration of lipophilic agents with multiple protonation sites into bacterial cells: tetracyclines and fluoroquinolones as examples. Antimicrob. Agents Chemother. 37:1393-1399. [PMC free article] [PubMed]
13. Pannek, S., P. G. Higgins, P. Steinke, D. Jonas, M. Akova, J. A. Bohnert, H. Seifert, and W. V. Kern.2006. Multidrug efflux inhibition in Acinetobacter baumannii: comparison between 1-(1-naphthylmethyl)-piperazine and phenyl-arginine-beta-naphthylamide. J. Antimicrob. Chemother. 57:970-974. [PubMed]
14. Park, H. R., T. H. Kim, and K. M. Bark.2002. Physicochemical properties of quinolone antibiotics in various environments. Eur. J. Med. Chem. 37:443-460. [PubMed]
15. Sato, K., and T. Nakae.1991. Outer-membrane permeability of Acinetobacter calcoaceticus and its implication in antibiotic-resistance. J. Antimicrob. Chemother. 28:35-45. [PubMed]
16. Smith, S. M., R. H. K. Eng, and C. E. Cherubin.1988. Conditions affecting the results of susceptibility testing for the quinolone compounds. Chemotherapy 34:308-314. [PubMed]
17. Vila, J., J. Ruiz, P. Goni, and T. J. Deanta.1997. Quinolone-resistance mutations in the topoisomerase IV parC gene of Acinetobacter baumannii. J. Antimicrob. Chemother. 39:757-762. [PubMed]
18. Vila, J., J. Ruiz, P. Goni, A. Marcos, and T. J. de Anta.1995. Mutation in the gyrA gene of quinolone-resistant clinical isolates of Acinetobacter baumannii. Antimicrob. Agents Chemother. 39:1201-1203. [PMC free article] [PubMed]
19. Wisplinghoff, H., M. Decker, C. Haefs, O. Krut, G. Plum, and H. Seifert.2002. Mutations in gyrA and parC associated with resistance to fluoroquinolones in epidemiologically defined clinical strains of Acinetobacter baumannii. J. Antimicrob. Chemother. 51:177-180. [PubMed]
20. Wohlert, S.-E., T. Jaetsch, B. Gallenkamp, H. J. Knops, N. Lui, M. Preiss, D. Haebich, and H. Labischinski.2008. New fluoroquinolone finafloxacin HCl (FIN): route of synthesis, physicochemical characteristics and activity under neutral and acid conditions, poster F1-2036. 48th Annu. Intersci. Conf. Antimicrob. Agents Chemother. (ICAAC)-Infect. Dis. Soc. Am. (IDSA), Washington, DC.

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)